10-Q quarterly report · filed Nov 2, 2026

Axsome Therapeutics, Inc. (AXSM) Q3 2026 10-Q Quarterly Report

Short answer

Axsome Therapeutics, Inc. (AXSM) filed its Q3 2026 10-Q quarterly report on Nov 2, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $260M (up 51.9% year over year) with net income of −$13M.

Q3 2026 key financials · XBRL

Revenue
$260M
+51.9% YoY · +18.9% QoQ
Net income
−$13M
+72.7% YoY · +74.9% QoQ
Operating margin
-4.3%
EPS (diluted)
−$0.23
+75.8% YoY · +76.8% QoQ

Source: XBRL data from the Axsome Therapeutics, Inc. (AXSM) Q3 2026 10-Q on SEC EDGAR. USD.

Axsome Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $259.7M, up from $171.0M YoY, driven by product sales of $250.0M
  • AUVELITY best performer: sales $207.6M vs $136.1M YoY
  • SYMBRAVO lowest sales: $3.9M vs $2.1M YoY
  • Operating loss $11.1M vs $46.1M; operating margin -4.3% vs -27.0% YoY
  • Nine-month operating cash use $63.1M vs $74.8M; financing provided $54.8M, including $19.5M equity proceeds
  • Outlook: SG&A marginally higher through 2026, R&D moderately higher; cash expected to fund operations into cash-flow positivity

Risk Factors

  • Regulatory risk: Canada Revenue Agency examination of 2024 and 2025 Canadian income tax returns remains ongoing
  • Legal risk: Second SYMBRAVO patent infringement action against Apotex commenced August 31, 2026
  • Operational risk: Limited contract manufacturers, sometimes only one supplier for products
  • Financial risk: $70.0 million Revolver outstanding at September 30, 2026, repaid in October 2026
  • Concentration risk: Majority of $313.9 million cash held by two financial institutions above insurance limits

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Axsome Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.